Candel Therapeutics (NASDAQ:CADL) Rating Increased to Hold at Wall Street Zen

Candel Therapeutics (NASDAQ:CADL) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

Several other equities research analysts have also issued reports on CADL. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Monday, April 20th. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Citigroup reduced their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, March 13th. Cantor Fitzgerald began coverage on Candel Therapeutics in a report on Monday, April 20th. They set an “overweight” rating on the stock. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 13th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Candel Therapeutics Price Performance

Candel Therapeutics stock opened at $8.30 on Monday. Candel Therapeutics has a one year low of $4.35 and a one year high of $9.27. The business has a fifty day moving average price of $6.50 and a 200-day moving average price of $5.81. The company has a debt-to-equity ratio of 0.34, a current ratio of 28.05 and a quick ratio of 28.05. The firm has a market capitalization of $608.14 million, a P/E ratio of -8.47 and a beta of -0.49.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.16. As a group, equities research analysts forecast that Candel Therapeutics will post -0.97 EPS for the current year.

Institutional Trading of Candel Therapeutics

Several large investors have recently modified their holdings of CADL. BNP Paribas Financial Markets grew its holdings in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after acquiring an additional 4,439 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Candel Therapeutics by 361.7% in the second quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock worth $49,000 after acquiring an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Candel Therapeutics in the 4th quarter worth $51,000. ProShare Advisors LLC purchased a new stake in shares of Candel Therapeutics in the 4th quarter worth $59,000. Finally, Invesco Ltd. purchased a new stake in shares of Candel Therapeutics in the 1st quarter worth $59,000. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.